On June 30, Tianjin Pharmaceutical Holdings released an announcement stating that its Methylprednisolone Tablets have recently been granted a pharmaceutical registration certificate by Belarus, permitting the production and marketing of the product in Belarus.The product is an oral tablet with a 4mg strength. As a widely used clinical corticosteroid, it is indicated for the treatment of a wide range of conditions including rheumatic disorders, collagen diseases, dermatoses, allergic reactions, ophthalmic diseases and respiratory ailments.Tianjin Pharmaceutical Holdings submitted the registration application to the Ministry of Health of Belarus in January 2026 and successfully obtained the registration certificate in June. This expedited approval not only verifies that the company’s products meet international quality and compliance standards, but also boosts the product’s market competitiveness. It creates new opportunities for the company’s finished dosage business to expand into Belarus and fuels revenue growth.Moving forward, Tianjin Pharmaceutical Holdings will pursue an upgraded Version 2.0 global expansion strategy, shifting focus from simply exporting finished products to exporting comprehensive pharmaceutical capabilities. The company will accelerate its international footprint across three core dimensions: aligning production and quality systems with global benchmarks, building international R&D and registration expertise, and advancing cross-border market deployment.

Source: Board Office of Tianjin Pharmaceutical Holdings, China Securities Journal · cnstock.com